All Title Author
Keywords Abstract


Atypical Antipsychotics in the Treatment of Depressive and Psychotic Symptoms in Patients with Chronic Schizophrenia: A Naturalistic Study

DOI: 10.1155/2013/423205

Full-Text   Cite this paper   Add to My Lib

Abstract:

Objectives. The aim of this naturalistic study was to investigate whether treatment with clozapine and other atypical antipsychotics for at least 2 years was associated with a reduction in psychotic and depressive symptoms and an improvement in chronic schizophrenia patients’ awareness of their illness. Methods. Twenty-three adult outpatients (15 men and 8 women) treated with clozapine and 23 patients (16 men and 7 women) treated with other atypical antipsychotics were included in the study. Psychotic symptoms were evaluated using the Positive and Negative Syndrome Scale (PANSS), depressive symptoms were assessed with the Calgary Depression Scale for Schizophrenia (CDSS), and insight was assessed with the Scale to Assess Unawareness of Mental Disorder (SUMD). Results. The sample as a whole had a significant reduction in positive, negative, and general symptoms, whereas the reduction in depression was significant only for patients with CDSS scores of 5 and higher at the baseline. At the follow-up, patients treated with other atypical antipsychotics reported a greater reduction in depression than patients treated with clozapine, but not when limiting the analyses to those with clinically relevant depression. Conclusions. Atypical antipsychotics may be effective in reducing psychotic and depressive symptoms and in improving insight in patients with chronic schizophrenia, with no differences in the profiles of efficacy between compounds. 1. Introduction Schizophrenia is a serious and disabling mental disorder usually associated with a decline in social and occupational functioning, and deficits in communication, control of behavior, the ability to feel pleasure, will, and initiative. The disease affects approximately 1% of the world’s population, or around 1–12 adults in every 1,000, mostly in the 15–35 year-old group [1–3]. Yearly incidence is 16–40 cases per 100,000 according to the ICD-9 criteria and 7–14 cases per 100,000 using more restrictive criteria [4, 5]. The risk of developing schizophrenia during a lifetime is around 0.7% (95% confidence interval (CI): 0.3%–2.0%) [3]. The longitudinal course of schizophrenia is characterized by recurrent episodes of illness, periods of complete or partial remission, and often chronicity. Schizophrenia is linked to functional and social disability, it impacts the patients’ ability to engage in productive work and social relationships, and it is associated with a reduced life expectancy as a result of accidents, high comorbidity with medical conditions, and suicide [6–17]. Furthermore, depression in schizophrenic

References

[1]  World Health Organisation, Schizophrenia, vol. 2012, World Health Organisation, Geneva, Switzerland, 2012.
[2]  R. Tandon, M. S. Keshavan, and H. A. Nasrallah, “Schizophrenia, “just the facts” what we know in 2008. 2. Epidemiology and etiology,” Schizophrenia Research, vol. 102, no. 1–3, pp. 1–18, 2008.
[3]  S. Saha, D. Chant, J. Welham, and J. McGrath, “A systematic review of the prevalence of schizophrenia,” PLoS Medicine, vol. 2, no. 5, article e141, 2005.
[4]  N. Sartorius, A. Jablensky, A. Korten et al., “Early manifestations and first-contact incidence of schizophrenia in different cultures,” Psychological Medicine, vol. 16, no. 4, pp. 909–928, 1986.
[5]  A. Jablensky, N. Sartorius, G. Ernberg et al., “Schizophrenia manifestations, incidence and course in different cultures. A World Health Organization ten-country study,” Psychological Medicine, vol. 22, no. 20, pp. 1–97, 1992.
[6]  M. T. Tsuang and R. F. Woolson, “Excess mortality in schizophrenia and affective disorders. Do suicides and accidental deaths solely account for this excess?” Archives of General Psychiatry, vol. 35, no. 10, pp. 1181–1185, 1978.
[7]  M. T. Tsuang, R. F. Woolson, and J. A. Fleming, “Premature deaths in schizophrenia and affective disorders. An analysis of survival curves and variables affecting the shortened survival,” Archives of General Psychiatry, vol. 37, no. 9, pp. 979–983, 1980.
[8]  C. B. Caldwell and I. I. Gottesman, “Schizophrenics kill themselves too: a review of risk factors for suicide,” Schizophrenia Bulletin, vol. 16, no. 4, pp. 571–590, 1990.
[9]  R. Tandon, H. A. Nasrallah, and M. S. Keshavan, “Schizophrenia, “just the facts” 4. Clinical features and conceptualization,” Schizophrenia Research, vol. 110, no. 1–3, pp. 1–23, 2009.
[10]  D. A. Casey, M. Rodriguez, C. Northcott, G. Vickar, and L. Shihabuddin, “Schizophrenia: medical illness, mortality, and aging,” International Journal of Psychiatry in Medicine, vol. 41, pp. 245–251, 2011.
[11]  A. Lwin, C. Symeon, F. Jan, and A. Sule, “Morbidity and mortality in schizophrenia,” British Journal of Hospital Medicine, vol. 72, no. 11, pp. 628–630, 2011.
[12]  T. M. Laursen, “Life expectancy among persons with schizophrenia or bipolar affective disorder,” Schizophrenia Research, vol. 131, no. 1–3, pp. 101–104, 2011.
[13]  P. Allebeck, “Schizophrenia: a life-shortening disease,” Schizophrenia Bulletin, vol. 15, no. 1, pp. 81–89, 1989.
[14]  M. Pompili, G. Serafini, M. Innamorati et al., “Suicide risk in first episode psychosis: a selective review of the current literature,” Schizophrenia Research, vol. 129, no. 1, pp. 1–11, 2011.
[15]  M. Shepherd, D. Watt, I. Falloon, and N. Smeeton, “The natural history of schizophrenia: a five-year follow-up study of outcome and prediction in a representative sample of schizophrenics,” Psychological Medicine, vol. 19, no. 15, pp. 1–46, 1989.
[16]  S. G. Siris, “Suicide and schizophrenia,” Journal of Psychopharmacology, vol. 15, no. 2, pp. 127–135, 2001.
[17]  C. B. Caldwell and I. I. Gottesman, “Schizophrenia-a high-risk factor for suicide: clues to risk reduction,” Suicide & Life-Threatening Behavior, vol. 22, no. 4, pp. 479–493, 1992.
[18]  C. Mulholland and S. Cooper, “The symptom of depression in schizophrenia and its management,” Advances in Psychiatric Treatment, vol. 6, pp. 169–177, 2000.
[19]  Y. Conwell, P. R. Duberstein, C. Cox, J. H. Herrmann, N. T. Forbes, and E. D. Caine, “Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study,” The American Journal of Psychiatry, vol. 153, no. 8, pp. 1001–1008, 1996.
[20]  J. H. Kim, J. H. Ann, and M. J. Kim, “Relationship between improvements of subjective well-being and depressive symptoms during acute treatment of schizophrenia with atypical antipsychotics,” Journal of Clinical Pharmacy and Therapeutics, vol. 36, no. 2, pp. 172–178, 2011.
[21]  J. Bobes, A. Ciudad, E. álvarez, L. San, P. Polavieja, and I. Gilaberte, “Recovery from schizophrenia: results from a 1-year follow-up observational study of patients in symptomatic remission,” Schizophrenia Research, vol. 115, no. 1, pp. 58–66, 2009.
[22]  G. D. Tollefson and S. W. Andersen, “Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?” The Journal of Clinical Psychiatry, vol. 60, no. 5, pp. 23–30, 1999.
[23]  R. R. Conley, “The burden of depressive symptoms in people with schizophrenia,” The Psychiatric Clinics of North America, vol. 32, no. 4, pp. 853–861, 2009.
[24]  S. G. Siris, “Depression in schizophrenia: perspective in the era of 'atypical' antipsychotic agents,” The American Journal of Psychiatry, vol. 157, no. 9, pp. 1379–1389, 2000.
[25]  J. D. Huppert, K. A. Weiss, R. Lim, S. Pratt, and T. E. Smith, “Quality of life in schizophrenia: contributions of anxiety and depression,” Schizophrenia Research, vol. 51, no. 2-3, pp. 171–180, 2001.
[26]  K. Sim, R. Mahendran, S. G. Siris, S. Heckers, and S. A. Chong, “Subjective quality of life in first episode schizophrenia spectrum disorders with comorbid depression,” Psychiatry Research, vol. 129, no. 2, pp. 141–147, 2004.
[27]  L. Hansson, “Determinants of quality of life in people with severe mental illness,” Acta psychiatrica Scandinavica. Supplementum., no. 429, pp. 46–50, 2006.
[28]  J. M. Narvaez, E. W. Twamley, C. L. McKibbin, R. K. Heaton, and T. L. Patterson, “Subjective and objective quality of life in schizophrenia,” Schizophrenia Research, vol. 98, no. 1–3, pp. 201–208, 2008.
[29]  M. Pompili, X. F. Amador, P. Girardi et al., “Suicide risk in schizophrenia: learning from the past to change the future,” Annals of General Psychiatry, vol. 6, article 10, 2007.
[30]  A. Roy, A. Mazonson, and D. Pickar, “Attempted suicide in chronic schizophrenia,” British Journal of Psychiatry, vol. 144, no. 3, pp. 303–306, 1984.
[31]  C. P. Miles, “Conditions predisposing to suicide: a review,” Journal of Nervous and Mental Disease, vol. 164, no. 4, pp. 231–246, 1977.
[32]  R. Dutta, R. M. Murray, M. Hotopf, J. Allardyce, P. B. Jones, and J. Boydell, “Reassessing the long-term risk of suicide after a first episode of psychosis,” Archives of General Psychiatry, vol. 67, no. 12, pp. 1230–1237, 2010.
[33]  B. A. Palmer, V. S. Pankratz, and J. M. Bostwick, “The lifetime risk of suicide in schizophrenia: a reexamination,” Archives of General Psychiatry, vol. 62, no. 3, pp. 247–253, 2005.
[34]  J. A. Worrel, P. A. Marken, S. E. Beckman, and V. L. Ruehter, “Atypical antipsychotic agents: a critical review,” American Journal of Health-System Pharmacy, vol. 57, no. 3, pp. 238–258, 2000.
[35]  P. M. Llorca and J. J. Pere, “Clozapine, 10 years after—a clinical review,” L'Encéphale, vol. 30, no. 5, pp. 474–491, 2004.
[36]  D. Naber and M. Lambert, “The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians,” CNS Drugs, vol. 23, no. 8, pp. 649–659, 2009.
[37]  G. Foussias and G. Remington, “Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making,” Canadian Journal of Psychiatry, vol. 55, no. 3, pp. 117–125, 2010.
[38]  T. C. Manschreck, D. A. Redmond, S. F. Candela, and B. A. Maher, “Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia,” Journal of Neuropsychiatry and Clinical Neurosciences, vol. 11, no. 4, pp. 481–489, 1999.
[39]  M. Bourin, B. Guitton, E. Dailly, P. Hery, and P. Jolliet, “A follow-up study of a population of schizophrenic patients treated with clozapine,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 25, no. 8, pp. 1481–1495, 2001.
[40]  J. A. Lieberman, G. Tollefson, M. Tohen et al., “Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol,” The American Journal of Psychiatry, vol. 160, no. 8, pp. 1396–404, 2003.
[41]  National Collaborating Centre for Mental Health, The NICE Guideline on Core Interventions in the Treatment and Management of Schizophrenia in Adults in Primary and Secondary Care, The British Psychological Society and the Royal College of Psychiatrists, London, UK, 2010.
[42]  M. Dossenbach, C. Arango-Dávila, H. S. Ibarra et al., “Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study,” The Journal of Clinical Psychiatry, vol. 66, no. 8, pp. 1021–1030, 2005.
[43]  M. Dossenbach, A. Erol, M. E. M. Kessaci et al., “Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol,” The Journal of Clinical Psychiatry, vol. 65, no. 3, pp. 312–321, 2004.
[44]  H. G. El-Sayeh, C. Morganti, and C. E. Adams, “Aripiprazole for schizophrenia: systematic review,” British Journal of Psychiatry, vol. 189, pp. 102–108, 2006.
[45]  D. Novick, J. M. Haro, D. Suarez, E. Vieta, and D. Naber, “Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study,” Schizophrenia Research, vol. 108, no. 1–3, pp. 223–230, 2009.
[46]  J. Geddes, N. Freemantle, P. Harrison, and P. Bebbington, “Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis,” British Medical Journal, vol. 321, no. 7273, pp. 1371–1376, 2000.
[47]  S. Leucht, G. Pitschel-Walz, D. Abraham, and W. Kissling, “Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials,” Schizophrenia Research, vol. 35, no. 1, pp. 51–68, 1999.
[48]  S. C. Schulz, R. Thomson, and M. Brecher, “The efficacy of quetiapine vs. haloperidol and placebo: a meta-analytic study of efficacy,” Schizophrenia Research, vol. 62, no. 1-2, pp. 1–12, 2003.
[49]  S. Caccia, L. Pasina, and A. Nobili, “New atypical antipsychotics for schizophrenia: iloperidone,” Drug Design, Development and Therapy, no. 4, pp. 33–48, 2010.
[50]  K. Salimi, L. F. Jarskog, and J. A. Lieberman, “Antipsychotic drugs for first-episode schizophrenia: a comparative review,” CNS Drugs, vol. 23, no. 10, pp. 837–855, 2009.
[51]  M. Riedel, N. Müller, M. Stradding, I. Spellmann, E. Severus, and H. J. M?ller, “Quetiapine in the treatment of schizophrenia and related disordes,” Neuropsychiatric Disease and Treatment, vol. 3, no. 2, pp. 219–235, 2007.
[52]  S. Leucht, C. Corves, D. Arbter, R. R. Engel, C. Li, and J. M. Davis, “Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis,” The Lancet, vol. 373, no. 9657, pp. 31–41, 2009.
[53]  T. S. Harrison and C. M. Perry, “Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder,” Drugs, vol. 64, no. 15, pp. 1715–1736, 2004.
[54]  A. DeLeon, N. C. Patel, and M. L. Crismon, “Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability,” Clinical Therapeutics, vol. 26, no. 5, pp. 649–666, 2004.
[55]  D. Naber and M. Lambert, “Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism,” Progress in Neuro-Psychopharmacology & Biological Psychiatry, vol. 28, no. 8, pp. 1213–1219, 2004.
[56]  S. A. M. K. Houthoofd, M. Morrens, and B. G. C. Sabbe, “Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder,” Clinical Therapeutics, vol. 30, no. 9, pp. 1565–1589, 2008.
[57]  T. S. Stroup, “Heterogeneity of treatment effects in schizophrenia,” American Journal of Medicine, vol. 120, no. 4, pp. S26–S31, 2007.
[58]  L. P. Henry, G. P. Amminger, M. G. Harris et al., “The EPPIC follow-up study of first-episode psychosis: longer-term clinical and functional outcome 7 years after index admission,” The Journal of Clinical Psychiatry, vol. 71, no. 6, pp. 716–728, 2010.
[59]  A. Karow, S. Moritza, M. Lambert, D. Sch?ttle, and D. Naber, “Remitted but still impaired? Symptomatic versus functional remission in patients with schizophrenia,” European Psychiatry, vol. 27, no. 6, pp. 401–405, 2012.
[60]  B. J. Kinon, L. Chen, H. Ascher-Svanum et al., “Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia,” Schizophrenia Research, vol. 102, no. 1–3, pp. 230–240, 2008.
[61]  H. Ascher-Svanum, A. W. Nyhuis, D. E. Faries, B. J. Kinon, R. W. Baker, and A. Shekhar, “Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia,” Schizophrenia Bulletin, vol. 34, no. 6, pp. 1163–1171, 2008.
[62]  S. Miyamoto, G. E. Duncan, C. E. Marx, and J. A. Lieberman, “Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs,” Molecular Psychiatry, vol. 10, no. 1, pp. 79–104, 2005.
[63]  J. A. Lieberman, “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials,” The Journal of Clinical Psychiatry, vol. 68, no. 2, p. e04, 2007.
[64]  J. A. Lieberman, T. Scott Stroup, J. P. McEvoy et al., “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia,” The New England Journal of Medicine, vol. 353, no. 12, pp. 1209–1223, 2005.
[65]  S. Z. Levine and S. Leucht, “Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories,” Biological Psychiatry, vol. 68, no. 1, pp. 86–92, 2010.
[66]  J. Rabinowitz, S. Z. Levine, R. Haim, and H. H?fner, “The course of schizophrenia: progressive deterioration, amelioration or both?” Schizophrenia Research, vol. 91, no. 1–3, pp. 254–258, 2007.
[67]  J. M. Haro, D. Suarez, D. Novick, J. Brown, J. Usall, and D. Naber, “Three-year antipsychotic effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results,” European Neuropsychopharmacology, vol. 17, no. 4, pp. 235–244, 2007.
[68]  G. B. Cuyún Carter, D. R. Milton, H. Ascher-Svanum, and D. E. Faries, “Sustained favorable long-term outcome in the treatment of schizophrenia: a 3-year prospective observational study,” BMC Psychiatry, vol. 11, p. 143, 2011.
[69]  A. Farahani and C. U. Correll, “Are antipsychotics or antidepressants needed for psychotic depression? A systematic review and meta-analysis of trials comparing antidepressant or antipsychotic monotherapy with combination treatment,” The Journal of Clinical Psychiatry, vol. 73, pp. 486–496, 2012.
[70]  G. D. Tollefson, T. M. Sanger, Y. Lu, and M. E. Thieme, “Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol,” Archives of General Psychiatry, vol. 55, no. 3, pp. 250–258, 1998.
[71]  G. D. Tollefson, T. M. Sanger, C. M. Beasley, and P. V. Tran, “A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia,” Biological Psychiatry, vol. 43, no. 11, pp. 803–810, 1998.
[72]  M. McDonagh, K. Peterson, S. Carson, R. Fu, and S. Thakurta, Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report, Oregon Health & Science University, Portland, OR, USA, 2010.
[73]  M. C. Mauri, D. Moliterno, M. Rossattini, and A. Colasanti, “Depression in schizophrenia: comparison of first- and second-generation antipsychotic drugs,” Schizophrenia Research, vol. 99, no. 1–3, pp. 7–12, 2008.
[74]  S. Pallanti, L. Quercioli, and A. Pazzagli, “Effects of clozapine on awareness of illness and cognition in schizophrenia,” Psychiatry Research, vol. 86, no. 3, pp. 239–249, 1999.
[75]  J. H. Kim, J. H. Ann, and J. Lee, “Insight change and its relationship to subjective well-being during acute atypical antipsychotic treatment in schizophrenia,” Journal of Clinical Pharmacy and Therapeutics, vol. 36, pp. 687–694, 2011.
[76]  S. R. Kay, L. A. Opler, and J. P. Lindenmayer, “Reliability and validity of the positive and negative syndrome scale for schizophrenics,” Psychiatry Research, vol. 23, no. 1, pp. 99–108, 1988.
[77]  D. Addington, J. Addington, and B. Schissel, “A depression rating scale for schizophrenics,” Schizophrenia Research, vol. 3, no. 4, pp. 247–251, 1990.
[78]  X. F. Amador and D. H. Strauss, The Scale to Assess Unawareness of Mental Disorder (SUMD), New York State Psychiatric Institute, Columbia University, New York, NY, USA, 1990.

Full-Text

comments powered by Disqus